Gilead Sciences’ (GILD) CEO Daniel O’Day is MIA, and so is the biotech’s promised return to growth.
O’Day, the longtime Roche executive, was named Gilead’s new CEO in December, but here we are two months later and he’s not yet shown up on the job. Commitments with Roche won’t allow O’Day to take over the Gilead executive suite until March 1, a Gilead spokesperson said.
That’s understandable, to a point, but his delayed start is a waste of valuable time. The J.P. Morgan Healthcare Conference in January and Monday night’s fourth-quarter earnings conference call would have been ideal venues for O’Day to lay out a strategic vision for Gilead. His absence during both events were badly missed opportunities.